Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
Key Points. CAR-T cell therapy demonstrates superior efficacy to bispecific antibody in DLBCL treatment, with higher complete response rates.CAR-T cell the